Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Ramos, Edneia A S ^a   Camargo, Anamaria A ^b   Braun, Karin ^a   Slowik, Renata ^a   Cavalli, Iglenir J ^a   Ribeiro, Enilze M S F ^a   Pedrosa, Fábio de O ^a   de Souza, Emanuel M ^a   Costa, Fabrício F ^c   Klassen, Giseli ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ESTROGEN RECEPTOR ALPHA; STROMAL CELL DERIVED FACTOR 1; CXCL12 PROTEIN, HUMAN; ESR1 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; PROGNOSIS; PROMOTER REGION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGED; BIOSYNTHESIS; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOKINE CXCL12; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77649314541     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-23     Document Type: Article

References (34)

1. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 2006, 25(3):357-371. 10.1007/s10555-006-9003-5, 17016763.
2. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4(7):540-550. 10.1038/nrc1388, 15229479.
3. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56. 10.1038/35065016, 11242036.
4. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16(1):6-21. 10.1101/gad.947102, 11782440.
5. Seniski GG, Camargo AA, Ierardi DF, Ramos EA, Grochoski M, Ribeiro ES, Cavalli IJ, Pedrosa FO, de Souza EM, Zanata SM, et al. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer 2009, 9:80. 10.1186/1471-2407-9-80, 2660367, 19267929.
6. Wendt MK, Cooper AN, Dwinell MB. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene 2007, 27(10):1461-1471. 10.1038/sj.onc.1210751, 17724466.
7. Wendt MK, Johanesen PA, Kang-Decker N, Binion DG, Shah V, Dwinell MB. Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 2006, 25(36):4986-4997. 10.1038/sj.onc.1209505, 16568088.
8. Giacinti L, Claudio PP, Lopez M, Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006, 11(1):1-8. 10.1634/theoncologist.11-1-1, 16401708.
9. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001, 61(19):7025-7029.
10. Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, Ralhan R. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007, 81(4):280-287. 10.1016/j.lfs.2007.05.012, 17599361.
11. Zhao L, Wang L, Jin F, Ma W, Ren J, Wen X, He M, Sun M, Tang H, Wei M. Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer. Breast Cancer Res Treat 2008,
12. Stamps AC, Davies SC, Burman J, O'Hare MJ. Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer 1994, 57(6):865-874. 10.1002/ijc.2910570616, 8206680.
13. Harris RA, Eichholtz TJ, Hiles ID, Page MJ, O'Hare MJ. New model of ErbB-2 over-expression in human mammary luminal epithelial cells. Int J Cancer 1999, 80(3):477-484. 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W, 9935193.
14. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003, 17(5):792-803. 10.1210/me.2002-0438, 12586845.
15. Veronesi U, Viale G, Rotmensz N, Goldhirsch A. Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. Breast 2006, 15(1):3-8. 10.1016/j.breast.2005.11.011, 16473737.
16. Sambrook J, Russel DW. Molecular cloning: A laboratory manual. 2001, New York: Cold Spring Harbor Laboratory.
17. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, Honjo T. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 1995, 28(3):495-500. 10.1006/geno.1995.1180, 7490086.
18. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005, 21(13):2933-2942. 10.1093/bioinformatics/bti473, 15860560.
19. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93(18):9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
20. Li S, Rong M, Iacopetta B. DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 2006, 237(2):272-280. 10.1016/j.canlet.2005.06.011, 16029926.
21. Costa FF, Paixao VA, Cavalher FP, Ribeiro KB, Cunha IW, Rinck JA, O'Hare M, Mackay A, Soares FA, Brentani RR, et al. SATR-1 hypomethylation is a common and early event in breast cancer. Cancer Genet Cytogenet 2006, 165(2):135-143. 10.1016/j.cancergencyto.2005.07.023, 16527607.
22. Garcia-Moruja C, Alonso-Lobo JM, Rueda P, Torres C, Gonzalez N, Bermejo M, Luque F, Arenzana-Seisdedos F, Alcami J, Caruz A. Functional characterization of SDF-1 proximal promoter. J Mol Biol 2005, 348(1):43-62. 10.1016/j.jmb.2005.02.016, 15808852.
23. Gruber CJ, Gruber DM, Gruber IM, Wieser F, Huber JC. Anatomy of the estrogen response element. Trends Endocrinol Metab 2004, 15(2):73-78. 10.1016/j.tem.2004.01.008, 15036253.
24. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
25. Jenuwein T. The epigenetic magic of histone lysine methylation. FEBS J 2006, 273(14):3121-3135. 10.1111/j.1742-4658.2006.05343.x, 16857008.
26. Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr Relat Cancer 2001, 8(2):115-127. 10.1677/erc.0.0080115, 11446343.
27. Zhou W, Jiang Z, Liu N, Xu F, Wen P, Liu Y, Zhong W, Song X, Chang X, Zhang X, et al. Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas. J Cancer Res Clin Oncol 2008, 135(1):91-102. 10.1007/s00432-008-0435-x, 18670789.
28. Antequera F, Bird A. CpG islands as genomic footprints of promoters that are associated with replication origins. Curr Biol 1999, 9(17):R661-667. 10.1016/S0960-9822(99)80418-7, 10508580.
29. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, et al. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 2007, 3(6):e87. 10.1371/journal.pgen.0030087, 1885282,1885282, 17542648.
30. Kishimoto H, Wang Z, Bhat-Nakshatri P, Chang D, Clarke R, Nakshatri H. The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12. Carcinogenesis 2005, 26(10):1706-1715. 10.1093/carcin/bgi137, 15917309.
31. Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 1998, 58(12):2515-2519.
32. Curradi M, Izzo A, Badaracco G, Landsberger N. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol Cell Biol 2002, 22(9):3157-3173. 10.1128/MCB.22.9.3157-3173.2002, 133775, 11940673.
33. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa JP, Davidson NE. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996, 2(5):805-810.
34. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004, 64(22):8184-8192. 10.1158/0008-5472.CAN-04-2045, 15548683.